{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"5","upperLimit":"NA","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Overall survival is defined as the length of time from start of treatment to death from any cause. Estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nVorinostat: Given PO","id":"OG000","title":"Arm I (Capecitabine, Vorinostat)"}],"paramType":"MEDIAN","populationDescription":"16 patients of the 25 were eligible for response assessment.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Survival","type":"SECONDARY","unitOfMeasure":"months"}